Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2019-04-02 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience: Nya prekliniska data för ATOR-1144 visar potential för aktivering av såväl det medfödda som det förvärvade immunsystemet samt direkt anti-tumöreffekt
Regulatory Filings Classification · 1% confidence The document is a press release dated April 2, 2019, from Alligator Bioscience announcing that they will present new preclinical data for their drug candidate ATOR-1144 at the AACR scientific conference. It details the scientific findings (mechanism of action, target expression) and mentions that a poster presentation will occur, with the poster content being made available on the company website. The text explicitly states that the information is being made public under EU market abuse regulations. Since this is an announcement about scientific data presentation and the release itself is short and focuses on disseminating news rather than being a comprehensive financial report (like 10-K or IR), it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. However, because it is a press release announcing scientific progress and data presentation, and it doesn't fit the specific definitions for ER, IR, or MDA, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of corporate news release, although it contains scientific information typical of an IP. Given the context of a press release announcing data presentation at a conference, RNS is the safest general classification for corporate news that isn't a formal financial report or specific management discussion.
2019-04-02 Swedish
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that new preclinical data for their drug candidate ATOR-1144 will be presented at the AACR scientific conference. It details the scientific findings and mentions the specific poster presentation time and title. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIV. Since it is an announcement about scientific data presentation, it best fits the category of general corporate/investor information that doesn't fit the highly specific financial codes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for corporate announcements that are not strictly financial results or management changes, although 'Investor Presentation' (IP) might seem close, this is an announcement *about* a presentation, not the presentation itself. However, given the context of a biotech company announcing scientific data presentation, this is a standard investor relations communication. Since there is no specific 'Scientific Update' code, and it is not a formal financial report, RNS is the most appropriate fallback for a general corporate update/announcement.
2019-04-02 English
Annual Report 2018
Annual Report Classification · 1% confidence The document is explicitly titled '2018 ANNUAL REPORT' and 'ALLIGATOR'S ANNUAL REPORT'. It contains comprehensive sections including an administration report, financial statements (Group and Parent Company), auditor's report, and management commentary. It covers the full fiscal year 2018 and provides detailed financial data, making it a standard 10-K equivalent (Annual Report). FY 2018
2019-03-22 English
Annual Report 2018
Annual Report Classification · 1% confidence The document is titled '2018 ÅRSREDOVISNING' (Annual Report 2018) for Alligator Bioscience AB. It contains comprehensive sections including a management report, financial statements (income statement, balance sheet, cash flow), notes, and an auditor's report. It is a full-year financial report, not an announcement or a summary, fitting the definition of an Annual Report (10-K). FY 2018
2019-03-22 Swedish
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that they will present preclinical data for their drug candidate ATOR-1017 at an upcoming Immuno-oncology Summit. It details the scientific findings, quotes management, and includes standard company boilerplate. This type of announcement, which is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), or a management change (MANG), fits best under the general category of Investor Relations or a specific announcement related to research/pipeline updates. Since it is an announcement about presenting data, and not the presentation itself (IP) or a formal earnings release (ER), it functions as a general corporate update aimed at investors. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate news that doesn't fit the highly specific categories like DIV, DIRS, or MANG, especially since it is a press release format. However, upon re-evaluation against the definitions, this document is primarily communicating scientific progress and pipeline updates to investors. It is not a formal regulatory filing (RNS) unless it were mandatory disclosure under EU Market Abuse Regulation (which it mentions, but the content is scientific news). It is not an Investor Presentation (IP) as it is a text release, not the presentation slides. It is not an Earnings Release (ER). Since it is a general announcement of corporate activity/news, RNS (Regulatory Filings/Miscellaneous Announcement) is the best fit among the provided codes for non-standard, non-financial core reports.
2019-03-18 English
Alligator Bioscience: Nya prekliniska data visar att 4-1BB-antikroppen ATOR-1017 ger kraftfulla anti-tumöreffekter
Regulatory Filings Classification · 1% confidence The document is a press release dated March 18, 2019, announcing new preclinical data for the drug candidate ATOR-1017, which will be presented at a scientific conference. It details scientific findings, quotes management, and includes standard boilerplate information about the company and regulatory disclosure regarding EU Market Abuse Regulation. This type of announcement, focusing on scientific updates, data presentation schedules, and pipeline progress, is characteristic of an Investor Presentation (IP) or a general press release related to investor relations. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR/IR), and it contains detailed scientific and strategic information aimed at investors, 'Investor Presentation' (IP) is the closest fit, although it is technically a press release announcing data presentation. Given the options, 'IP' covers detailed scientific/pipeline updates presented to investors. However, since this is a news announcement about data being presented, and not the presentation itself, it could also be considered a general Regulatory Filing (RNS) or a communication related to investor information. Given the depth of the scientific update and the context of presenting data, IP is a strong candidate, but the structure is that of a press release. Since it is not a formal report, and it is not a management discussion (MDA), the most appropriate category for a detailed scientific/pipeline update press release that isn't a standard ER or IR is often RNS if a better fit doesn't exist. Let's re-evaluate: It's an announcement of data being presented at a conference. This is often categorized as an Investor Presentation (IP) if the content mirrors what would be in a presentation deck, or RNS if it's just a regulatory news service announcement. Because it details the specific presentation title and timing, it strongly relates to investor communication about pipeline progress, making IP plausible. However, if we strictly follow the definitions, it's a news announcement about scientific progress, which often falls under RNS (Regulatory Filings/General Announcements) when it's not a formal financial report (ER, IR) or a specific management/board change. Given the focus on preclinical data and conference presentation, it is a form of investor communication. I will classify it as RNS as it is a general regulatory news announcement about scientific progress, which is a common use case for RNS when other categories like ER or IR do not apply.
2019-03-18 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.